Phase 3
N=321
Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction
Acute Pain
Bottom Line
View on ClinicalTrials.gov: NCT04622735 ↗Enrolled (actual)
321
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h) — 8955.4; 8458.0; 5290.7 score on a scale — p=0.0031
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- nefopam hydrochloride 30mg / paracetamol 500mg X2 (Combination_product); Paracetamol 500 Mg Oral Tablet X2 (Drug); Nefopam HCl 30 MG Oral Tablet X2 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Unither Pharmaceuticals, France
- Primary completion
- Oct 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ranked Endpoints : 1. Sum of Pain Intensity Differences at 6 Hours (SPID0-6h) |
8955.4; 8458.0; 5290.7 | 0.0031 sig |
| PRIMARY Total Pain Relief at 6 Hours (TOTPAR0-6h) |
610.6; 602.2; 461.4 | — |
| PRIMARY Proportion of Responder Patients |
47; 43; 35 | — |
| PRIMARY The Patient's Global Impression of Change (PGIC) Questionnaire |
11; 14; 11; 39; 29; 30 | — |
| PRIMARY The Onset of Pain Relief |
76; 74; 58 | — |
| SECONDARY Total Pain Relief at 1 Hour (TOTPAR0-1h), 2 Hours (TOTPAR0-2h), 3 Hours (TOTPAR0-3h), and 4 Hours (TOTPAR0-4h) |
60.2; 69.4; 49.7; 170.0; 183.0; 133.2 | — |
| SECONDARY Sum of Pain Intensity Differences at 1 Hour (SPID0-1h), 2 Hours (SPID0-2h), 3 Hours (SPID0-3h), and 4 Hours (SPID0-4h) |
743.7; 809.5; 506.4; 2405.9; 2418.4; 1487.2 | — |
| SECONDARY The Pain Intensity Differences (PID) Assessment |
-11.4; -14.8; -8.6; -20.1; -19.6; -12.7 | — |
| SECONDARY Proportion of Responder Patients. |
44; 45; 34; 57; 54; 38 | — |
| SECONDARY Time to the Second Investigational Medicinal Product (IMP) Intake |
438.5; 429.0; 387.0 | — |
| SECONDARY Participant Having Taken a Rescue Analgesic Treatment |
19; 26; 35 | — |
| SECONDARY Sum of Pain Intensity Differences |
23306.5; 22173.7; 19910.3; 48792.4; 44604.7; 42972.1 | — |
| SECONDARY Proportion of Patients Having Taken a Rescue Analgesic Treatment Throughout the Study. |
19; 26; 35 | — |
| SECONDARY The Total Dose of Rescue Medication Taken. |
7.1; 7.3; 6.0 | — |
| SECONDARY Mean Duration Under Rescue Medication Over the 5 Days. |
57.9; 99.4; 61.9 | — |
| SECONDARY Number of Investigational Medicinal Product (IMP) Intakes |
6.4; 5.8; 5.1 | — |
| SECONDARY Patient's Global Impression of Change (PGIC) Score |
36; 39; 34; 40; 46; 40 | — |
Summary
This study aims to evaluate the analgesic efficacy of single and multiple doses of a new fixed dose combination of nefopam hydrochloride 30 mg and paracetamol 500mg taken orally in comparison to each single component.
Eligibility Criteria
Main Inclusion Criteria:
- Male and female patient aged from 18 years up to 65 years,
- Patient scheduled to undergo the surgical removal of at least one fully or partially impacted third mandibular molar requiring bone removal under short-acting local anaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,
- Patient weighing > 50 kg,
- Patient who has signed a written informed consent prior to any study-related procedures.
Additional inclusion criteria after surgery (randomization):
- Patient experiencing moderate to severe pain within 4 hours after the dental extraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score ≥ 50 mm,
- Third molar extraction(s) completed without any immediate complication, that in the opinion of the investigator, would interfere with the study conduct and/or assessments (e.g., suspected neurosensory complication, incomplete removal of tooth)
Main Exclusion Criteria:
- Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within 3 days preceding the day of randomization or within 5 times the elimination half-life whichever the longest,
- Woman with positive results on a urine pregnancy test or breastfeeding woman or woman of childbearing potential without an effective contraception,
- Patient with a history of convulsive disorders,
- Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited to selegiline, isocarboxazid, tranylcypromine, phenelzine…),
- Patient with an abnormal cardiac condition: medically significant disorders of cardiac rate and/or rhythm,
- Patient with known anaemia,
- Patient with known pulmonary disease,
- Patient with known active gastric or duodenal ulcer or a history of recurrent gastrointestinal ulcer/bleeding,
- Patient with known glaucoma,
- Patients with a prostatic hyperplasia or urinary retention,
- Patient with current or chronic history of liver disease, or known hepatic or biliary abnormalities,
- Patient with a current or chronic history of severe renal impairment (glomerular filtration below 30 mL/min),
Data sourced from ClinicalTrials.gov (NCT04622735). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.